{"id":458491,"date":"2021-03-16T08:03:15","date_gmt":"2021-03-16T12:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=458491"},"modified":"2021-03-16T08:03:15","modified_gmt":"2021-03-16T12:03:15","slug":"neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/","title":{"rendered":"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PITTSBURGH, March  16, 2021  (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical &amp; Scientific Conference being held from March 15-18, 2021. The presentation, entitled <em>Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled Therapy,<\/em> will provide an overview of NeuBase\u2019s positive <em>in vitro <\/em>and <em>in vivo<\/em> preclinical data for its PATrOL\u2122-enabled therapy for the treatment of myotonic dystrophy type 1 (DM1).<\/p>\n<p align=\"left\">\n        <strong>Presentation Details<\/strong><br \/>\n        <br \/>\n        <strong>Title: <\/strong>Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled Therapy<br \/><strong>Presenter: <\/strong>Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase <br \/><strong>Date: <\/strong>March 18, 2021 <br \/><strong>Time: <\/strong>9:30 a.m.-9:45 a.m. EDT<\/p>\n<p align=\"left\">For more information and to register for the conference, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=71nNCiFIwDehxvu8KqpZvaz48V89opjA9lb4yFWNYQMVBtyxrHJrZzQrqydY7oT9ULpyLM1z8DvtP1EWgpe9YnsRkDGzx8BNqhToft3p7es=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/mdaconference.org\/<\/a>.<\/p>\n<p align=\"left\">\n        <strong>About NeuBase Therapeutics, Inc.<\/strong><br \/>\n        <br \/>NeuBase is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase&#8217;s designer PATrOL\u2122 therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.<\/p>\n<p align=\"left\">\n        <strong>Use of Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as &#8220;will,&#8221; &#8220;would,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;designed,&#8221; &#8220;plan,&#8221; or &#8220;intend,&#8221; the negative of these terms, and similar references to future periods. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company&#8217;s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company&#8217;s plans to develop and commercialize its product candidates; the timing of initiation of the Company&#8217;s planned clinical trials; the timing of the availability of data from the Company&#8217;s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company&#8217;s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company&#8217;s product candidates; the Company&#8217;s commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company&#8217;s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.<\/p>\n<p align=\"left\">\n        <strong>NeuBase Investor Contact:<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zOL2Dnsm6la5CeIIbKgL8xx4xJOUKe8ME19aUTQl0zUe_OQol1Ql9mF_AGxgO0B3G7cr6-RwFY-FRQV5r-5FObk14ERfLuH1VRCt6G8eohaJ5wKWtpFtjpFCDnc5Kxx4\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><br \/>OP: (617) 535-7746<\/p>\n<p align=\"left\">\n        <strong>NeuBase Media Contact:<\/strong><br \/>\n        <br \/>Cait Williamson, Ph.D.<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2GYSwBWSfzIaX8ZbChHvVe8oyEq-ccpZ5W0fiUtDfugM1FpJgNZ3WYH_XjiwH8fPMtsHh5u4GGdALy9PzHUzwauCNZd5JdcDs-EBjEPe4GI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cait@lifescicomms.com<\/a><br \/>OP: (646) 751-4366<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/cbbaf971-6cc7-4d90-b5fb-39fb58bc362d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical &amp; Scientific Conference being held from March 15-18, 2021. The presentation, entitled Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled Therapy, will provide an overview of NeuBase\u2019s positive in vitro and in vivo preclinical data for its PATrOL\u2122-enabled therapy for the treatment of myotonic dystrophy type 1 (DM1). Presentation Details Title: Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled TherapyPresenter: Dietrich A. Stephan, Ph.D., Chief Executive Officer of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-458491","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical &amp; Scientific Conference being held from March 15-18, 2021. The presentation, entitled Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled Therapy, will provide an overview of NeuBase\u2019s positive in vitro and in vivo preclinical data for its PATrOL\u2122-enabled therapy for the treatment of myotonic dystrophy type 1 (DM1). Presentation Details Title: Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled TherapyPresenter: Dietrich A. Stephan, Ph.D., Chief Executive Officer of &hellip; Continue reading &quot;NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-16T12:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference\",\"datePublished\":\"2021-03-16T12:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/\"},\"wordCount\":702,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/\",\"name\":\"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==\",\"datePublished\":\"2021-03-16T12:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/","og_locale":"en_US","og_type":"article","og_title":"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference - Market Newsdesk","og_description":"PITTSBURGH, March 16, 2021 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today an oral presentation at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical &amp; Scientific Conference being held from March 15-18, 2021. The presentation, entitled Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled Therapy, will provide an overview of NeuBase\u2019s positive in vitro and in vivo preclinical data for its PATrOL\u2122-enabled therapy for the treatment of myotonic dystrophy type 1 (DM1). Presentation Details Title: Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL\u2122-Enabled TherapyPresenter: Dietrich A. Stephan, Ph.D., Chief Executive Officer of &hellip; Continue reading \"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-16T12:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference","datePublished":"2021-03-16T12:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/"},"wordCount":702,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/","name":"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==","datePublished":"2021-03-16T12:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE5MDMyNCM0MDY0OTUwIzUwMDA2NDg3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-therapeutics-to-present-at-the-2021-muscular-dystrophy-association-virtual-clinical-scientific-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuBase Therapeutics to Present at the 2021 Muscular Dystrophy Association Virtual Clinical &amp; Scientific Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=458491"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/458491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=458491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=458491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=458491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}